Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection

René Zeiss*, Bernhard J. Connemann, Carlos Schönfeldt-Lecuona and Maximilian Gahr

Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany

Introduction: It has not yet been possible to demonstrate the well-established increased bleeding risk related to antidepressants (ADs) with methods of pharmacovigilance as disproportionality analysis. As bleeding events related to ADs often occur under comedication with antithrombotics, ADs might not be considered causative of, but merely “linked” with the bleeding event. Therefore, we hypothesized that causality assessment of bleeding events related to ADs and the competitive impact of antithrombotics are factors contributing to the mentioned previous non-findings.

Methods: We performed a case/non-case study based on data from VigiBase™ and calculated reporting odds ratios (RORs) for 25 ADs. We used individual case safety reports (ICSRs) that were differently categorized in the database regarding the type of association between drug and event. Furthermore, we investigated the competitive impact of antithrombotics by comparing RORs calculated with and without ICSRs related to antithrombotics.

Results: Analysis of ICSRs that were categorized as causally associated with ADs resulted in detection of only 2 signals (citalopram and escitalopram; upper gastrointestinal bleeding). Analysis of ICSRs irrespective of the type of association resulted in detection of 8 signals (regarding bleeding in general, gastrointestinal bleeding and upper gastrointestinal bleeding). In our analysis, consideration of ICSRs associated with antithrombotics as competitive substances did not have significant impact on signal detection.

Conclusion: Categorization of the type of association between drug and event may affect quantitative signal detection toward reduced sensitivity. Causality assessment seems to significantly impact signal detection, probably particularly in rare, unknown, or clinically unremarkable adverse drug reactions. ADs appear to increase the bleeding risk considerably, even independent of antithrombotic comedication.

Keywords: antidepressants, serotonin transporter, bleeding risk, pharmacovigilance, competition bias
INTRODUCTION

Antidepressants (ADs) are frequently used in the treatment of depression, anxiety disorders, and several other mental disorders (1–4). In addition, the use of antidepressants has also increased in the elderly population and in patients suffering from severe somatic illnesses (e.g., acute coronary syndrome) (5). However, in the last years, several studies suggested an increased bleeding risk related to ADs, particularly agents that inhibit the reuptake of serotonin, and in regard to particular risk groups, e.g., patients taking antithrombotic drugs (6, 7). There are studies suggesting an increased risk for brain haemorrhages (8, 9), peri- and postoperative bleeding (10), and gastrointestinal haemorrhages (11), especially of the upper gastrointestinal tract (12–14) related to ADs. Until now it was not possible to demonstrate the otherwise well-established increased risk of bleeding related to ADs with disproportionality analysis using data of pharmacovigilance databases (15, 16). We hypothesize that insufficient consideration of comedication and reporter-related factors that affect causality assessment and documentation of adverse drug reaction (ADR) reports in the database may be relevant for these non-findings. Furthermore, in the analysis of data from pharmacovigilance databases, such as the European EudraVigilance, the FDA Adverse Event Reporting System (FAERS) or the adverse drug reaction (ADR) database of the WHO, VigiBase™, several biases need to be taken into account, for example, the notoriety bias (17), underreporting (18, 19), and the competition bias (20, 21). The competition bias describes the phenomenon that a substance or an event that is frequently associated with the event of interest may (competitively) “mask” a substance-related signal (20, 22). Moreover, the evaluation of the type of the association between drug and event by the person who reports the respective ADR (=reporter) may affect the results of signal detection, too. Drug/event associations can be reported to the ADR database as “concomitant” (not suspected as causally linked, but merely “associated”) or “suspected/interacting” (suspected as causally linked). According to the International Council for Harmonization (ICH) guidelines, the characterization of the drug’s causality for the event is made by the primary reporter. For instance, a bleeding event occurring under a medication including a selective serotonin reuptake inhibitor (SSRI) and a non-steroidal anti-inflammatory drug (NSAID) could be reported as an ADR caused by the NSAID alone, if the reporting person is unfamiliar with the bleeding risk related to SSRI. As a consequence, the association with the SSRI is documented as “concomitant” in the database, and a possible causal relation is not adequately considered. The impact of the categorization as “concomitant” or “suspected/interacting” on the results of disproportionality analysis regarding the bleeding risk of ADs has not yet been studied. This consideration might be of particular importance as disproportionality analysis has not yet been able to demonstrate the bleeding risk related to ADs. Therefore, in the present paper, we (i) evaluated the impact of the categorization of drug/event (ADs/haemorrhages) reports as causally linked (category: “suspected/interacting”) versus all types of association/irrespective of the type of association (category: “suspected/interacting/concomitant”) on signal detection, (ii) evaluated the risk of different types of bleeding events (haemorrhages, in general, gastrointestinal bleeding and upper gastrointestinal bleeding) related to antidepressants, and (iii) analyzed the impact of the competition bias by evaluating the role of antithrombotics as competitive substances.

METHODS

Database and Database Query

The collection of data was done by a data search query at VigiBase™ (date of database query: December 10, 2018) using terms of the Medical Dictionary for Regulatory Activities (MedDRA). VigiBase™ contains over 20 million reports of individual case safety reports (ICSRs) (23). The search terms used were the standardized MedDRA Queries (SMQs) “Haemorrhage” (narrow scope), “Gastrointestinal haemorrhage,” and the preferred term (PT) “Upper gastrointestinal haemorrhage.” The MedDRA Version used was 21.1. The number of ICSRs related to the following ADs associated with each of the abovementioned conditions were extracted: agomelatine, amitriptyline, bupropion, citalopram, clomipramine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, hypericum perforatum, imipramine, maprotiline, milnacipran, mirtazapine, moclobemide, nortriptyline, paroxetine, reboxetine, sertraline, tianeptine, tranylcypromine, trazodone, trimipramine, and venlafaxine.

Categorization of Individual Case Safety Reports

In the first analysis, the categorization chosen for the database query was “suspected/interacting” and, for the second analysis, “suspected/interacting/concomitant.” The categorization of a drug/event report as “suspected,” respectively, “interacting” (meaning that a causal relation between the drug and event is assumed) or “concomitant” (meaning that only an association between drug and event in the database is present, e.g., the drug is part of a polypharmacy and administered before or during the occurrence of the event of interest) is made by the primary reporter of the ICSR. All drugs that are considered as “interacting” are also considered to be “suspected” drugs in the database (24). Drugs that are considered as neither “suspected” nor “interacting” are categorized as “concomitant.” The category used in the second analysis was “suspected/interacting/concomitant” and comprises all ICSRs irrespective of the available information regarding the type of the association between drug and event.

Statistical Analysis

We performed a case/non-case study and calculated the reporting odds ratios (ROR) and the 95% confidence intervals (CI) for disproportionality analysis. For this type of study, all reports associated with the respective substance and the ADR of interest are defined as “cases” and all other reports in the database as “non-cases.” If an ADR related to a certain substance is reported more frequently in comparison with all other substances in the database, this is referred to as
a signal. In this study, a signal is defined as a ROR \(>1\) with a lower limit of the 95% CI \(>1\). First, the RORs were calculated for both datasets (“suspected/interacting” and “suspected/interacting/concomitant”); in the second dataset (“suspected/interacting/concomitant”), the competitive impact of antithrombotics was evaluated as described in the following paragraph (2.4). In a previous analysis where only ICSRs categorized as “suspected/interacting” were analyzed, the effects of the competition bias, i.e., the comparison of RORs calculated with vs. without inclusion of ICSRs associated with antithrombotics, were found to be negligible [see Zeiss et al. (25) for details]. Data analysis was performed with Microsoft Excel Version 16.16.8 and RStudio Version 1.2.5019.

**Competition Bias**

For the dataset “suspected/interacting/concomitant,” we made the calculation without considering the competition bias by using the entire data available in the database. For consideration of the competition bias, we calculated the RORs after removing all reports associated with a substance of the group “antithrombotic agents” [Anatomical Therapeutic Chemical (ATC) Classification System code B01]. These substances were chosen because haemorrhages are considered as a so-called type A reaction related to antithrombotic agents, meaning that the ADR is a consequence of the pharmacological effect and therefore very common (22).

**RESULTS**

At the time of the database query, there were 18,709,028 ICSRs in VigiBase, 990,119 of them were associated with the SMQ “Haemorrhage,” 257,500 with the SMQ “Gastrointestinal Haemorrhage,” and 10,908 with the PT “Upper gastrointestinal haemorrhage.” In the following, we will present the signals found for each of the investigated SMQs, respectively, PT, first in the analysis of ICSRs that were categorized as “suspected/interacting/concomitant.” For the latter, signals detected after removal of ICSRs related to antithrombotics are additionally presented. The comparison between the ROR values for “suspected/interacting” vs. “suspected/interacting/concomitant” is presented in Supplementary Tables S1–S3.

**Standardized MedDRA Queries “Haemorrhage”**

In the analysis of ICSRs categorized as “suspected/interacting” concerning the SMQ “haemorrhage” (ICSRs related to antithrombotics included; no consideration of the competition bias), no signal was found; using ICSRs categorized as “suspected/interacting/concomitant,” eight signals were detected: amitriptyline [ROR: 1.09 (95% CI, 1.06–1.12)], citalopram [ROR: 1.41 (1.38–1.45)], escitalopram [ROR: 1.35 (1.32–1.39)], fluoxetine [ROR: 1.03 (1.01–1.05)], hypericum perforatum [ROR: 1.26 (1.10–1.45)], paroxetine [ROR: 1.05 (1.02–1.07)], sertraline [ROR: 1.22 (1.20–1.25)], and trazodone [ROR: 1.28 (1.25–1.32)]. After removal of ICSRs related to antithrombotics (i.e., consideration of the competition bias), nine signals were found (using ICSRs categorized as “suspected/interacting/concomitant”): Two new signals related to venlafaxine [ROR: 1.06 (1.02–1.09) and duloxetine [ROR: 1.07 (1.04–1.11)] were detected, while the signal related to paroxetine became non-significant [ROR 1.02 (0.99–1.05)]; the other signals persisted. Regarding the ROR values including the 95% CI for each substance for SMQ “Haemorrhage,” see Table 1.

**Table 1** Reporting odds ratios and 95% CIs related to antidepressants and the SMQ “Haemorrhage” with and without consideration of the competition bias.

| Substance           | ROR without consideration of the competition bias | ROR in consideration of the competition bias |
|---------------------|--------------------------------------------------|---------------------------------------------|
| Agomelatine         | 0.54 (0.45–0.65)                                  | 0.59 (0.47–0.73)                            |
| Amitriptyline       | 1.09 (1.06–1.12)                                  | 1.17 (1.13–1.21)                            |
| Bupropion           | 0.79 (0.77–0.81)                                  | 0.93 (0.90–0.96)                            |
| Citalopram          | 1.41 (1.38–1.45)                                  | 1.33 (1.29–1.37)                            |
| Clomipramine        | 0.59 (0.54–0.65)                                  | 0.67 (0.60–0.74)                            |
| Doxepin             | 0.99 (0.92–1.06)                                  | 1.04 (0.95–1.13)                            |
| Duloxetine          | 0.97 (0.95–1.00)                                  | 1.07 (1.04–1.11)                            |
| Escitalopram        | 1.35 (1.32–1.39)                                  | 1.31 (1.27–1.36)                            |
| Fluoxetine          | 1.03 (1.01–1.05)                                  | 1.19 (1.16–1.22)                            |
| Fluvoxamine         | 0.62 (0.57–0.68)                                  | 0.74 (0.67–0.82)                            |
| Hypericum perforatum| 1.26 (1.10–1.45)                                  | 1.62 (1.40–1.89)                            |
| Imipramine          | 0.80 (0.73–0.87)                                  | 0.90 (0.82–1.00)                            |
| Maprotiline         | 0.52 (0.44–0.62)                                  | 0.59 (0.49–0.72)                            |
| Mirtazapine         | 0.77 (0.68–0.87)                                  | 0.94 (0.82–1.08)                            |
| Moclobemide         | 1.04 (1.00–1.08)                                  | 0.82 (0.78–0.86)                            |
| Norflurpridine      | 1.06 (1.00–1.12)                                  | 1.17 (1.09–1.26)                            |
| Paroxetine          | 1.05 (1.02–1.07)                                  | 1.02 (0.99–1.05)                            |
| Reboxetine          | 0.40 (0.31–0.51)                                  | 0.54 (0.41–0.70)                            |
| Sertraline          | 1.22 (1.20–1.25)                                  | 1.28 (1.24–1.31)                            |
| Tianeptine          | 1.10 (0.95–1.26)                                  | 0.49 (0.38–0.65)                            |
| Tranylcypromine     | 0.72 (0.58–0.88)                                  | 0.98 (0.79–1.21)                            |
| Trazodone           | 1.28 (1.25–1.32)                                  | 1.26 (1.22–1.31)                            |
| Trimipramine        | 0.86 (0.75–0.98)                                  | 0.90 (0.76–1.06)                            |
| Venlafaxine         | 0.97 (0.95–1.00)                                  | 1.06 (1.02–1.09)                            |

CI, confidence interval; ROR, reporting odds ratio; SMQ, standardized MedDRA queries.

**Standardized MedDRA Queries “Gastrointestinal Haemorrhage”**

In the analysis of ICSRs categorized as “suspected/interacting” concerning the SMQ “Gastrointestinal Haemorrhage” (ICSRs related to anti-thrombotics included; no consideration of the competition bias), no signals were found. Using ICSRs categorized as “suspected/interacting/concomitant,” eight signals were found: amitriptyline [ROR: 1.43 (95% CI, 1.37–1.50)], citalopram [ROR: 1.67 (1.60–1.74)], doxepin [ROR: 1.28 (1.14–1.43)], escitalopram [ROR: 1.37 (1.30–1.43)], mirtazapine [ROR: 1.41 (1.33–1.49)], paroxetine [ROR: 1.10 (1.05–1.15)], sertraline [ROR: 1.31 (1.26–1.36)], and trazodone [ROR: 1.56 (1.49–1.64)].
TABLE 2 | Reporting odds ratios and 95% CIs related to antidepressants and the SMQ “Gastrointestinal Haemorrhage” with and without consideration of the competition bias.

| Substance | ROR without consideration of the competition bias | ROR in consideration of the competition bias |
|-----------|-----------------------------------------------|---------------------------------------------|
| Agomelatine | 0.42 (0.28–0.62) | 0.51 (0.31–0.84) |
| Amitriptyline | 1.43 (1.37–1.50) | 1.65 (1.55–1.75) |
| Bupropion | 0.69 (0.65–0.73) | 0.81 (0.75–0.88) |
| Citalopram | 1.67 (1.60–1.74) | 1.50 (1.41–1.60) |
| Clomipramine | 0.48 (0.40–0.58) | 0.57 (0.45–0.73) |
| Doxepin | 1.28 (1.14–1.43) | 1.43 (1.23–1.66) |
| Duloxetine | 1.01 (0.96–1.06) | 1.13 (1.05–1.20) |
| Escitalopram | 1.37 (1.30–1.43) | 1.30 (1.22–1.40) |
| Fluoxetine | 0.96 (0.92–1.00) | 1.07 (1.01–1.14) |
| Fluvoxamine | 0.63 (0.53–0.75) | 0.79 (0.64–0.97) |
| Hypericum perforatum | 1.02 (0.77–1.38) | 0.95 (0.63–1.43) |
| Imipramine | 0.95 (0.82–1.10) | 1.10 (0.91–1.33) |
| Maprotiline | 0.45 (0.32–0.63) | 0.51 (0.33–0.79) |
| Minipiprazine | 0.46 (0.34–0.62) | 0.54 (0.37–0.79) |
| Mirtazapine | 1.41 (1.33–1.49) | 1.10 (1.00–1.21) |
| Moclobemide | 0.46 (0.33–0.65) | 0.55 (0.36–0.84) |
| Nortriptyline | 1.05 (0.93–1.17) | 1.18 (1.02–1.38) |
| Paroxetine | 1.10 (1.05–1.15) | 1.04 (0.98–1.11) |
| Reboxetine | 0.37 (0.22–0.62) | 0.58 (0.34–1.00) |
| Sertraline | 1.31 (1.26–1.36) | 1.27 (1.20–1.34) |
| Tianeptine | 1.01 (0.77–1.34) | 0.48 (0.26–0.86) |
| Tranylcypromine | 0.27 (0.14–0.52) | 0.43 (0.21–0.85) |
| Trazodone | 1.56 (1.49–1.64) | 1.41 (1.31–1.52) |
| Trimipramine | 1.14 (0.91–1.43) | 1.31 (0.98–1.76) |
| Venlafaxine | 0.97 (0.93–1.02) | 1.10 (1.03–1.17) |

| Substance | ROR without consideration of the competition bias | ROR in consideration of the competition bias |
|-----------|-----------------------------------------------|---------------------------------------------|
| Agomelatine | NA | NA |
| Amitriptyline | 1.60 (1.31–1.96) | 2.08 (1.49–2.90) |
| Bupropion | 0.55 (0.40–0.76) | 0.46 (0.25–0.86) |
| Citalopram | 2.51 (2.14–2.93) | 2.18 (1.59–2.98) |
| Clomipramine | 0.22 (0.06–0.87) | 0.66 (0.17–2.65) |
| Doxepin | 1.49 (0.90–2.47) | 1.31 (0.49–3.48) |
| Duloxetine | 1.49 (1.23–1.81) | 1.53 (1.08–2.17) |
| Escitalopram | 2.23 (1.86–2.67) | 2.02 (1.42–2.88) |
| Fluoxetine | 1.11 (0.91–1.36) | 1.21 (0.86–1.72) |
| Fluvoxamine | 0.34 (0.11–1.07) | 0.70 (0.17–2.78) |
| Hypericum perforatum | 1.54 (0.50–4.78) | 3.27 (0.82–13.08) |
| Imipramine | 0.79 (0.36–1.76) | 0.41 (0.06–2.92) |
| Maprotiline | NA | NA |
| Minipiprazine | NA | NA |
| Mirtazapine | 3.05 (2.52–3.70) | 3.07 (2.14–4.39) |
| Moclobemide | NA | NA |
| Nortriptyline | 1.23 (0.74–2.04) | 1.40 (0.58–3.36) |
| Paroxetine | 1.36 (1.11–1.66) | 1.13 (0.77–1.68) |
| Reboxetine | 0.59 (0.08–4.21) | NA |
| Sertraline | 2.13 (1.84–2.45) | 1.68 (1.25–2.25) |
| Tianeptine | NA | NA |
| Tranylcypromine | NA | NA |
| Trazodone | 2.29 (1.89–2.77) | 2.34 (1.64–3.33) |
| Trimipramine | 0.71 (0.18–2.84) | 2.26 (0.57–9.05) |
| Venlafaxine | 1.15 (0.92–1.43) | 1.27 (0.87–1.86) |

CI, confidence interval; NA, data not available (<3 records); PT, preferred term; ROR, reporting odds ratio; SMQ, standardized MedDRA queries.

After removing reports associated with antithrombics from the database (i.e., consideration of the competition bias) 10 signals were found, from which four were new (using ICSRs categorized as “suspected/interacting/concomitant”): duloxetine [ROR: 1.15 (1.05–2.25)], doxepin [ROR: 1.28 (1.14–2.47)], amitriptyline [ROR: 1.31 (1.05–2.25)], and venlafaxine [ROR: 1.56 (1.06–2.29)]. Using ICSRs categorized as “suspected/interacting/concomitant,” eight signals were found: amitriptyline [ROR: 1.60 (95% CI, 1.31–1.96)], citalopram [ROR: 2.51 (2.14–2.93)], duloxetine [1.49 (1.23–1.81)], escitalopram [ROR: 2.23 (1.86–2.67)], mirtazapine [ROR: 3.05 (2.52–3.70)], paroxetine [ROR: 1.36 (1.11–1.66)], sertraline [ROR: 2.13 (1.84–2.45)], and trazodone [ROR: 2.29 (1.89–2.77)].

Preferred Term “Upper Gastrointestinal Haemorrhage”

In the analysis of ICSRs categorized as “suspected/interacting” regarding the PT “Upper gastrointestinal haemorrhage” (ICSRs related to antithrombics included; no consideration of the competition bias) two signals were found: citalopram [ROR: 1.61 (1.15–2.25)] and escitalopram [ROR: 1.56 (1.06–2.29)]. Using ICSRs categorized as “suspected/interacting/concomitant,” eight signals were found: amitriptyline [ROR: 1.60 (95% CI, 1.31–1.96)], citalopram [ROR: 2.51 (2.14–2.93)], duloxetine [1.49 (1.23–1.81)], escitalopram [ROR: 2.23 (1.86–2.67)], mirtazapine [ROR: 3.05 (2.52–3.70)], paroxetine [ROR: 1.36 (1.11–1.66)], sertraline [ROR: 2.13 (1.84–2.45)], and trazodone [ROR: 2.29 (1.89–2.77)].

DISCUSSION

In the present study, we evaluated whether the causality assessment/categorization of a drug/event report as causally linked (“suspected/interacting”) vs. any type of association...
("suspected/interacting/concomitant") has an impact on signal detection using an example of the bleeding risk related to ADs. Furthermore, we analyzed the risk of different types of bleeding events and the influence of the competition bias by evaluating the effect of antithrombotics as competitors.

**Effects of Different Types of Association of Drug/Event Reports on Signal Detection**

In a previous analysis, where we only analyzed causally linked drug/event-reports, we could not detect a significant number of signals, meaning that we were not able to demonstrate the well-known bleeding risk related to ADs (25). By contrast, in the present study, where we assessed ICSRs categorized as "suspected/interacting/concomitant," we found several signals concerning bleeding in general, gastrointestinal bleeding, and upper gastrointestinal bleeding. These findings strengthen the evidence for an increased bleeding risk of ADs, particularly concerning the risk of bleedings of the gastrointestinal tract (7, 11, 26–28). Moreover, the results of our study suggest that the use of association categories implying a causal link between drug and event may impede the detection of signals in disproportionality analysis. This may be particularly true regarding ADRs that are not well-known, hard to clinically identify, or difficult to assign to a specific drug, namely, rare, or non-severe/clinically insignificant ADRs. It was previously suggested that treatment with ADs increases the bleeding risk only slightly (29). Moreover, it is possible that there is limited awareness regarding the increased risk of bleeding related to ADs among possible reports, e.g., physicians or patients. This may favor the reporting of bleeding events without indicating ADs as possibly causally linked and, in turn, affect the results of signal detection depending on the assigned association category. Our approach, where we analyzed all types of associations irrespective of the available information regarding causality, reduces specificity; however, it increases the sensitivity of the analysis. This approach may help to detect unknown, rare, or non-severe (clinically insignificant) ADRs.

**Competition Bias**

Principally, by considering a possible competition bias caused by antithrombotic agents, there was no major impact of the competition bias on disproportionality analysis in the present study concerning ADs and bleeding; in other studies, however, the competition bias was found to be relevant for the sensitivity in signal detection (20–22): Pariente et al. unmasked signals for gastric and esophageal haemorrhages related to prednisone, rivastigmine, and isotretinoin regarding bleeding events by considering the competitive effects of antithrombotic agents (21): in a methodological work, the numbers of reports that are needed to detect a signal for bleeding events decreased after removing data related to competitive substances (22). In our study, however, after considering a possible competition bias caused by antithrombotic agents, we only found new signals for bleeding, in general, and for gastrointestinal bleeding related to the serotonin–norepinephrine reuptake inhibitors (SNRI) duloxetine and venlafaxine. In this regard, it has to be considered that antithrombotic agents are frequently associated with an increased risk of bleedings as their influence on hemostasis is desired, and bleeding can be a consequence of the pharmacological effect of the substance. Therefore, they are well-suited as competitors in the analyses of the bleeding events in pharmacovigilance databases (22). Several studies have consequently shown an even more increased risk of bleeding related to ADs combined with antithrombotic agents (6, 30, 31). In this regard, it has to be taken into account that in our study, we were indeed not able to “unmask” signals related to antidepressants after removal of ICSRs related to antithrombotics. However, signals related to ADs preponderantly persisted in all analyses, which speaks in favor of a relevant risk of bleeding related to ADs, even when administered without antithrombotics.

**Other Studies Regarding Abnormal Bleedings Related to Antidepressive Psychopharmacotherapy**

Our results are in line with the current literature regarding antidepressants with serotonin reuptake inhibition and an associated increased risk of bleeding. The bleeding risk related to antidepressants has not yet been demonstrated on the basis of data from spontaneous reporting systems. However, there are several studies demonstrating an increased risk for haemorrhages related to ADs with different methods. In a population-based cohort study by Renoux et al., an association between an antidepressant's affinity for the serotonin transporter and the risk of intracranial haemorrhage was found; the risk was even further increased with oral anticoagulants as comedication (8). In a case-control study with more than 64,000 antidepressant users, there was a 2.6-fold increased bleeding risk for substances with a high degree of serotonin reuptake inhibition compared with a low one (32). A recent meta-analysis of 42 observational studies regarding the bleeding risk of SSRI showed an increase in the bleeding risk by at least 36% (33).

**Risk of Bleeding Related to Localization: Sensitivity vs. Specificity?**

Taking into account the presumably particularly increased risk of bleeding related to ADs in the gastrointestinal tract [especially the upper gastrointestinal tract (11)], we also used more specific terms for the database query, namely, gastrointestinal haemorrhages and upper gastrointestinal haemorrhages. Although the case numbers were reduced in this subgroup analyses [total number of events “Haemorrhage” (SMQ): 990,119, “Gastrointestinal haemorrhage” (SMQ): 257,500, “Upper gastrointestinal haemorrhage” (PT): 10,908] several signals appeared, indicating an increased risk of bleeding events of the gastrointestinal tract related to ADs. These findings are in line with several studies about gastrointestinal bleeding events in association with antidepressant use. In an observational case-control study with 430,455 warfarin users, an increased risk of gastrointestinal bleeding was found for citalopram, fluoxetine, paroxetine, amitriptyline, and mirtazapine, which is in line with our findings except for fluoxetine (7). One retrospective cohort study with 317,824 elderly people enrolled found an association
between antidepressants with serotonin reuptake inhibition and upper gastrointestinal bleeding (11). However, there are also studies suggesting no (34) or only a modest increase (26) in risk for upper gastrointestinal haemorrhage in association with ADs, which might explain why, in previous studies with a more sensitive approach, we were not able to find any signals.

**LIMITATIONS**

One major limitation of the study is the common problem of underreporting in ADR databases (19, 35). In the special case of ADs and bleeding, this is of concern since bleeding events related to antidepressants could be frequently underreported because bleeding events like petechiae are often not severe and, thus, might not be reported (36). Another limitation of our study is the missing information on comedication besides the influence of antithrombotics, especially regarding NSAIDs that are also associated with an increased risk of bleeding, particularly regarding the upper gastrointestinal tract (37–40). In this analysis, out of the NSAIDs group, we only considered acetylsalicylic acid because it is also included in the antithrombotic agents group (ATC code B01), and the bleeding risk is considered a type A reaction. The influence of other NSAIDs (e.g., diclofenac or ibuprofen) that are associated with an increased risk of bleeding might also be relevant. Furthermore, since we have no data regarding actual prescription numbers, a quantitative comparison of the RORs in terms of the relative risk is not possible. A signal found with disproportionality analysis only show an association and does not allow deductions on absolute or relative risks.

**CONCLUSION**

This is the first time the bleeding risk related to ADs could be demonstrated using pharmacovigilance data. In contrast to previous studies, drug/event reports were analyzed irrespective of the available information regarding causality. The results of the present study suggest that in disproportionality analysis, the restriction to association categories that imply a causal link between drug and event may impede the detection of signals, particularly regarding ADRs that are rare, unknown, non-severe (clinically insignificant), hard to recognize, or difficult to assign to a specific drug. Even after removal of all reports associated with antithrombotic agents, there were still signals related to ADs regarding an increased bleeding risk, indicating there is a relevant risk of bleeding related to ADs even when administered without antithrombotics.

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found here: https://www.who-umc.org/vigibase/vigibase/.

**AUTHOR CONTRIBUTIONS**

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by RZ and MG. The first draft of the manuscript was written by RZ and MG. All authors commented on previous versions of the manuscript and read and approved the final manuscript.

**ACKNOWLEDGMENTS**

This study and the conclusions are those of the authors and do not represent the opinion of the UMC or the World Health Organization.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.727687/full#supplementary-material

**REFERENCES**

1. National Institute for Heath and Care Excellence. National Institute for Health and Care Excellence Depression in Adults: Treatment and Management. (2018). Available online at: https://www.nice.org.uk/guidance/gid-cgwave0725/documents/full-guideline-updated
2. National Institute for Health and Care Excellence. Generalised Anxiety Disorder and Panic Disorder in Adults: Management. Natt Inst Heal Clin Excell. (2016). Available online at: https://www.nice.org.uk/guidance/cg113
3. Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, et al. Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update. RTI Int North Carolina Chapel Hill Evidence-based Pract Cent. (2018) 616:72–5. doi: 10.23970/AHRQEPCCER207
4. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD). Washington, DC APA: Guidel Dev Panel Treat Posttraumatic Stress Disord Adults (2017). p. 139.
5. Czarny MJ, Arthurs E, Coffie DF, Smith C, Steele RJ, Ziegelstein RC, et al. Prevalence of antidepressant prescription or use in patients with acute coronary syndrome: a systematic review. PLoS ONE. (2011) 6:e27671. doi: 10.1371/journal.pone.0027671
6. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med. (2008) 168:180–5. doi: 10.1001/archinternmed.2007.32
7. Schelleman H, Brensinger CM, Bilker WB, Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS ONE. (2011) 6:e21447. doi: 10.1371/journal.pone.0021447
8. Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with spontaneous intracranial hemorrhage. JAMA Neurol. (2017) 74:173. doi: 10.1001/jamaneurol.2016.4529
9. Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. CNS Drugs. (2018) 32:321–34. doi: 10.1007/s40263-018-0507-7
10. Roose SP, Rutherford BR. Selective serotonin reuptake inhibitors and operative bleeding risk: a review of the literature. J Clin Psychopharmacol. (2016) 36:704–9. doi: 10.1097/JCP.0000000000000575
11. van Walraven C, Mandani MM, Wells PS, Williams JL. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding...
in elderly patients: retrospective cohort study. BMJ. (2001) 323:655–8. doi: 10.1136/bmj.323.7314.655

12. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interactions with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. (2008) 65:795–803. doi: 10.1001/archpsyc.65.7.795

13. de Abajo FJ, Rodríguez LA, Monterro D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: a population based case-control study. BMJ. (1999) 319:1106–9. doi: 10.1136/bmj.319.7121.1106

14. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a population-based cohort study. Arch Intern Med. (2003) 163:59–64. doi: 10.1001/archinte.163.1.59

15. Gahr M, Zeis R, Lang D, Connenmann BJ, Hiemcke C, Freudenmann RW, et al. Risk of bleeding related to selective and non-selective serotoninergic antidepressants: a case/non-case approach using data from two pharmacovigilance databases. Pharmacopsychiatry. (2015) 48:19–24. doi: 10.1055/s-0034-1394398

16. Maschino F, Hurault-Delarue C, Chebbane L, Fabry V, Montastruc JL, Bagheri M. Association of risk of abnormal bleeding with degree of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. (2014) 23:989–92. doi: 10.1002/pds.3622

17. Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci. (1999) 168:257–61. doi: 10.1007/BF02944353

18. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci. (1999) 168:257–61. doi: 10.1007/BF02944353

19. Salvo F, Leborgne F, Thiessard F, Moore N, Bégaud B, Pariente A. A population-based study of under-reporting of adverse drug reactions. Eur J Clin Pharmacol. (2012) 68:1557–60. doi: 10.1007/s00228-012-1268-8

20. Reissmann P, Karagaranam L, Abou Taam M, Roux MP, Drame M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. (2014) 23:989–92. doi: 10.1002/pds.3622

21. Pinheiro R, Feely J, Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci. (1999) 168:257–61. doi: 10.1007/BF02944353

22. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci. (1999) 168:257–61. doi: 10.1007/BF02944353

23. Reissmann P, Karagaranam L, Abou Taam M, Roux MP, Drame M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. (2014) 23:989–92. doi: 10.1002/pds.3622

24. Guideline on Clinical Safety Data Management E2B(R2) (2021). doi: 10.1007/s40801-021-00260-9. [Epub ahead of print].

25. Zeiss R, Hiemke C, Schönfeldt C, Connemann BJ, Gahr M. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. (2014) 109:811–9. doi: 10.1038/ajg.2014.82

26. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiads GJ, et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. (2014) 109:811–9. doi: 10.1038/ajg.2014.82

27. Wang YP, Chen YT, Tsai CF, Li SY, Luo JC, Wang SJ, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry. (2014) 171:54–61. doi: 10.1176/appi.ajp.2013.12111167

28. Jiang H-Y, Chen H-Z, Hu X-J, Yu Z-H, Yang W, Deng M, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. (2015) 13:42–50. doi: 10.1016/j.cgh.2014.06.021

29. Andrade C, Sandarsh S, Chethan KR, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. (2010) 71:1565–75. doi: 10.4088/JCP.09r05786hu

30. Hackam DG, Mzkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. (2012) 79:1862–5. doi: 10.1212/WNL.0b013e31827ff848

31. Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, Egberts AGC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. (2004) 164:2367. doi: 10.1001/archinte.164.21.2367

32. Laporte S, Chapelle C, Caillet P, Beyens M-N, Bellet F, Delavenne X, et al. Blurring risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. (2017) 118:19–32. doi: 10.1016/j.phrs.2016.08.017

33. Carvajal A, Ortega S, Del Olmo L, Vidal X, Aguirre C, Ruiz B, et al. Selective serotonin reuptake inhibitor and gastrointestinal bleeding: a case-control study. PLoS ONE. (2011) 6:e19819. doi: 10.1371/journal.pone.0019819

34. Hazell L, Shairk SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. (2006) 29:385–96. doi: 10.2165/00002018-200629050-00003

35. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug Saf. (2009) 32:19–31. doi: 10.2165/00002018-200902100-00002

36. de Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. (2003) 55:591–5. doi: 10.1046/j.0306-5251.2002.01777.x

37. Zullino DF, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSR/NSAID combination may be due to pharmacokinetic interactions. Br J Clin Pharmacol. (2005) 59:118–9. doi: 10.1111/j.1365-2125.2005.212_1.x

38. Shin J-Y, Park M-J, Lee SH, Choi S-H, Kim M-H, Choi N-K, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ. (2015) 351:h3517. doi: 10.1136/bmj.h3517

39. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding and effect of acid-suppressing agents. Aliment Pharmacol Ther. (2008) 27:31–40. doi: 10.1111/j.1365-2036.2007.03341.x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zeiss, Connemann, Schönfeldt-Lecuona and Gahr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.